Overview

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors

Status:
Unknown status

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

Well differentiated neuroendocrine (NE) carcinomas have low proliferative activity and conventional chemotherapy is not recommended. Metronomic chemotherapy, i.e. the frequent administration of cytotoxic drugs at low doses, has demonstrated antiangiogenetic properties. Since well differentiated NE carcinomas are highly vascular, there is a rationale for testing metronomic chemotherapy and antiangiogenetic drugs. This is a national, multicenter, phase II study.

Phase:

Phase 2

Details

Lead Sponsor:

University of Turin, Italy

Treatments:

Bevacizumab
Capecitabine
Octreotide
Somatostatin